For decades, pancreatic cancer patients have faced significant gaps in research funding, earlier detection technologies, and treatment options, contributing to devastating outcomes. Today, bold science and sustained investment are narrowing those gaps. Discoveries once thought impossible are driving meaningful progress for patients and creating new possibilities for the future.

As the world’s largest private funder of pancreatic cancer research, the Lustgarten Foundation has invested more than $333 million in the science behind this progress, from foundational discoveries to new treatment options reaching patients. But this is not the finish line.

This November, join Lustgarten as we highlight yesterday’s foundational discoveries, today’s breakthroughs, and tomorrow’s possibilities, while celebrating the community powering it all!

Together, we’re transforming pancreatic cancer into a curable disease.

Research has brought us closer.
Patients are counting on us to
continue the momentum.


As the world’s largest private funder of pancreatic cancer research, we are powering the discoveries that are changing the future of this disease.

$333 MILLION
Invested in pancreatic cancer research

386 PROJECTS
Advancing bold ideas and innovative science

86 INSTITUTIONS
Bringing the brightest minds together

And we’re not slowing down! Donate today to POWER THE RESEARCH!

Since our founding in 1998, Lustgarten has invested in bold ideas, pioneering researchers, and discoveries that once seemed out of reach.

That commitment is paying off.

From understanding the biology of pancreatic cancer to developing new targeted therapies, foundational research is changing how we detect, treat, and ultimately aim to prevent this disease.

Because the next breakthrough starts with the research we fund today.

EXPLORE OUR PROGRESS

RESEARCH MATTERS

For decades, KRAS mutations, found in more than 90% of pancreatic cancers, were considered ‘undruggable.’ Today, decades of scientific discovery and sustained investment have led to the first FDA-approved RAS-targeted therapy, Rasonque ™ (daraxonrasib), for metastatic pancreatic cancer.

This breakthrough didn’t happen overnight.

RESEARCH SPOTLIGHT:

Meet Team iPACK, led by Anirban Maitra, MD, Director of the Perlmutter Cancer Center at NYU Langone Health. Supported by Lustgarten’s Clinical Accelerator Initiative, the team is exploring how daraxonrasib could be used to intercept pancreatic cancer before it develops.

DISCOVER THE BREAKTHROUGH & BEYOND


Thanks for signing up!
Tell us a little more about yourself: